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Abstract
Meta-analyses in orphan diseases and small populations generally
face particular problems including small numbers of studies, small
study sizes, and heterogeneity of results. However, the heterogeneity
is difficult to estimate if only very few studies are included. Moti-
vated by a systematic review in immunosuppression following liver
transplantation in children we investigate the properties of a range of
commonly used frequentist and Bayesian procedures in extensive sim-
ulation studies. Furthermore, the consequences for interval estimation
of the common treatment effect in random effects meta-analysis are
assessed. The Bayesian credibility intervals using weakly informative
priors for the between-trial heterogeneity exhibited coverage probabil-
ities in excess of the nominal level for a range of scenarios considered.
However, they tended to be shorter than those obtained by the Knapp-
Hartung method, which were also conservative. In contrast, methods
based on normal quantiles exhibited coverages well below the nominal
levels in many scenarios. With very few studies, the performance of
the Bayesian credibility intervals is of course sensitive to the specifi-
cation of the prior for the between trial heterogeneity. In conclusion,
the use of weakly informative priors as exemplified by half-normal
priors (with scale 0.5 or 1.0) for log odds ratios is recommended for
applications in rare diseases.
1 Introduction
In the European Union a disease affecting 5 in 10,000 people is consid-
ered rare, whereas in the USA a condition affecting fewer than 200,000
∗correspondence to: Tim Friede, Department of Medical Statistics, University Medical
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people is defined as rare. As these examples show, no universal defini-
tion of rare diseases (also referred to as orphan disease) exists (Aronson,
2006). It is estimated that 6,000 to 8,000 rare diseases are known today
with numbers increasing as more diseases are discovered. Many of these
have a genetic component, are chronic as well as life-threatening and affect
children (see e.g. rarediseases.org or www.orpha.net). Examples of rare
diseases include childhood cancers, amyotrophic lateral sclerosis (ALS), and
Creutzfeldt-Jacob disease (CJD). More generally, small populations can oc-
cur by rare conditions or by stratification of more common diseases by e.g.
genetic markers.
Since rare diseases and small populations pose particular problems to de-
sign, conduct and analysis of clinical research due to the small sizes, various
efforts have been undertaken in tailoring methods specific for the applica-
tion in these populations (Gagne et al., 2014). Recent publications such
as Hampson et al. (2014); Speiser et al. (2015) demonstrate that this is an
ongoing effort which is also reflected in a recent funding initiative of the Eu-
ropean Commission supporting three research networks in developing clin-
ical research methodology suitable for rare diseases and small populations,
namely “Integrated Design and AnaLysis of small population group trials”
(IDEAL), “Advances in Small Trials dEsign for Regulatory Innovation and
eXcellence” (ASTERIX) and “Innovative methodology for small population
research” (InSPiRe). Also, regulatory authorities acknowledge the need for
innovative approaches to clinical trials in rare and very rare diseases (Euro-
pean Medicines Agency (EMEA), 2006). To our knowledge, however, neither
have the standard methods of meta-analysis been assessed for their suitabil-
ity to be applied in small populations and rare diseases nor have any specific
methods for meta-analysis been developed for these populations. This is
surprising, since it is generally accepted that meta-analytic methods are a
powerful tool to guide objective decision-making by allowing for the formal,
statistical combination of information to merge data from individual experi-
ments to a joint result.
There are some specific challenges for meta-analyses in small populations
and rare diseases. As will be seen in the motivating example of Section 2,
the number of studies included in meta-analyses is typically small, and the
studies themselves are rather small with many of them being inconclusive. In
this situation a formal synthesis of the available evidence is highly desirable.
However, the study designs often vary, for instance with regard to the type of
control groups (historical vs. concurrent controls) and treatment allocation
(non-randomized vs. randomized; allocation ratio), making between-trial
heterogeneity with regard to the treatment effects very likely. In fact, smaller
studies have empirically been found to exhibit more heterogeneity than large
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ones (IntHout et al., 2015). The situation gets even more difficult for rare
events (Sweeting et al., 2004; Bradburn et al., 2007; Kuß, 2015), but this is
not our scope here.
Many meta-analyses may be approached using approximately normal ef-
fect estimates and a normal random-effects model, the normal-normal hier-
archical model (Hedges and Olkin, 1985). The between-study heterogeneity
plays a central role in this context. Estimation of the heterogeneity variance
component based on only a few studies however is particularly challenging,
as the resulting uncertainty is often substantial and consistent with small to
large heterogeneity. Proper accounting for this uncertainty is crucial when
estimating effect sizes. Especially when the analysis is based on few studies,
which is a common problem not only for orphan diseases, the utilization of
a-priori information on heterogeneity may be helpful (Sutton and Abrams,
2001).
Our aim is to assess the properties of Bayesian and popular frequentist
methods in a simulation study covering typical scenarios for rare disease
as well as in a case study. We have developed a method to substantially
ease the computational burden of a Bayesian random-effects meta-analysis,
which avoids Markov chain Monte Carlo computations and facilitates large-
scale simulations. The method has been implemented in the bayesmeta
R package to be released soon.
The paper is organized as follows. In Section 2 we introduce a case study
in paediatric transplantation motivating our investigations. In Section 3 the
statistical model as well as the methods for meta-analysis are introduced that
are compared in an extensive simulation study in Section 4. The findings are
illustrated by revisiting the systematic review in paediatric transplantation
in Section 5. We close with a brief discussion.
2 A case study in paediatric transplantation
Several rare paediatric liver diseases can nowadays be successfully treated
by liver transplantation with good long-term outcomes (Spada et al., 2009;
Kosolo, 2013). One key component of a successful treatment is effective and
safe immunosuppresion after transplantation. A number of immunosuppres-
sant drugs with different mechanisms of action and associated adverse event
profiles are available and are given either as monotherapy or in combina-
tion (for an overview see e.g. Table 1 in Kosolo (2013)). Relatively new are
the Interleukin-2 receptor antibodies (IL-2RA) Basiliximab and Daclizumab.
Recently, Crins et al. (2014) conducted a systematic review of controlled, but
not necessarily randomized studies of IL-2RA in paediatric liver transplan-
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tation. Primary outcomes were acute rejections, steroid-resistant rejections,
graft-loss and death. For illustrative purposes we focus here on acute and
steroid-resistant rejections. A total of six studies were included in a meta-
analysis assessing the risk of acute rejections on treatments with IL-2RA in
comparison with control, whereas only three of these six studies reported
data on steroid-resistant rejections.
Crins et al. used the DerSimonian-Laird method and the restricted max-
imum-likelihood (REML) approach to estimate the between-study variance.
Although they reported treatment effects in terms of relative risks we use
here the odds ratio as it is the more commonly used measure. Figure 1
gives the numbers of patients and events by treatment group, and depicts
the odds ratios comparing IL-2RA treament with control in forest plots.
The 95% confidence intervals of the odds ratios were computed using normal
approximation on the log-scale (zero cell entries here were treated by adding
1
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to each cell of the corresponding contingency table).
Study
Heffron (2003)
Gibelli (2004)
Schuller (2005)
Ganschow (2005)
Spada (2006)
Gras (2008)
Events
14
16
 3
 9
 4
 0
Total
 61
 28
 18
 54
 36
 50
Experimental
Events
15
19
 8
29
11
 3
Total
 20
 28
 12
 54
 36
 34
Control
0.01 0.1 1 10
Odds Ratio
OR
0.10
0.63
0.10
0.17
0.28
0.09
95%−CI
[0.03; 0.32]
[0.21; 1.88]
[0.02; 0.56]
[0.07; 0.42]
[0.08; 1.00]
[0.00; 1.78]
Liver transplant example: acute rejection (AR)
Study
Heffron (2003)
Ganschow (2005)
Gras (2008)
Events
 2
 4
 1
Total
 61
 54
 50
Experimental
Events
 4
 6
 4
Total
 20
 54
 34
Control
0.01 0.1 1 10
Odds Ratio
OR
0.14
0.64
0.15
95%−CI
[0.02; 0.81]
[0.17; 2.41]
[0.02; 1.43]
Liver transplant example: steroid−resistant rejection (SRR)
Figure 1: Forest plots of odds ratios for acute rejections and steroid-resistant
rejections based on data from the systematic review by Crins et al. (2014).
The specific problems with meta-analyses in rare diseases outlined in
Section 1 are prominent here. First, the number of controlled studies is with
6 and 3 rather small, although the search was not restricted to randomized
studies only. Second, the total sample sizes varied from only 30 to 108. Third,
there are some marked differences in the designs employed. For instance, only
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the studies by Heffron (2003) and Spada (2006) were randomized, and some
of the non-randomized studies used concurrent controls whereas other relied
on historical control data. Finally, the allocation ratios ranged between 1:1
to 3:1. These variations in design lead to some heterogeneity in the results
as is apparent from the forest plots. In the next section we will summarize a
number of methods to quantify this heterogeneity.
3 Methods
The vast majority of meta-analyses use common effect (fixed effect) or ran-
dom effects models. For the latter, the normal-normal hierarchical model
(NNHM) is the most popular. It has two parts: a sampling and a parame-
ter model. The sampling model assumes approximately normally distributed
estimates Y1, . . . , Yk for the trial-specific parameters θ1, . . . , θk
Yj|θj ∼ N(θj , s2j), j = 1, . . . , k. (1)
Any estimation uncertainty in the standard errors sj is neglected here. The
parameter model softens the strong (common effect) assumption of parameter
equality to parameter similarity. The simplest similarity model assumes the
parameters as random (or exchangeable) effects
θj |µ, τ ∼ N(µ, τ 2), j = 1, . . . , k. (2)
Equivalently, this model introduces a variance component for between-trial
variability, θj = µ + ǫj , with ǫj ∼ N(0, τ 2). The between-trial standard
deviation τ determines the degree of similarity across parameters; the special
case τ = 0 corresponds to the common effect model.
The scope of the NNHM is broad. The focus can be on the trial-specific
parameters θj , the predicted parameter θk+1 in an new trial, or the mean
parameter µ. Here, we will be concerned with the latter. For this case,
inference can be simplified by considering only the marginal model
Yj |µ, τ ∼ N(µ, s2j + τ 2), j = 1, . . . , k. (3)
The two ways to infer the parameter of interest µ and the nuisance parameter
τ are classical and Bayesian. If τ were known, they would lead to the same
conclusions for µ. Classically,
µˆ =
k∑
j=1
wjYj/
k∑
j=1
wj ∼ N(µ, 1/w+) (4)
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where wj are the inverse-variance (precision) weights
wj = 1/(s
2
j + τ
2), j = 1, . . . k, (5)
and the total precision of the estimate is the sum of the marginal precisions,
w+ =
∑k
j=1wj. For known τ and a non-informative (improper) prior on µ,
the Bayesian result is
µ|Y1, . . . , Yk ∼ N(
k∑
j=1
wjYj/
k∑
j=1
wj, 1/w+). (6)
While this “equivalence” of classical and Bayesian results for µ is comforting,
it breaks down if τ is not known. For this case, classical methods to infer µ
involve two steps:
(1) an estimate τˆ is derived, which is then used to obtain the weights (5)
and the corresponding estimate for µ in (4);
(2) a confidence interval is derived. In this step the uncertainty for the
estimate τˆ is sometimes ignored, i.e., the normal approximation in (4)
with the plug-in estimate τˆ is used. Or, the uncertainty of τˆ is taken
into account, for example by the tk−1 approximation (Follmann and
Proschan, 1999), the profile likelihood method (Hardy and Thompson,
1996), or the method by Hartung and Knapp (Hartung and Knapp,
2001a,b; Knapp and Hartung, 2003).
For step (1) many methods have been proposed (e.g. DerSimonian and Kacker
(2007); Chung et al. (2013)). In the following sections we will use four esti-
mates:
• DL: the frequently used DerSimonian-Laird estimate (DerSimonian and
Laird, 1986) is a moment-based estimate for τ . The DL estimate does
not require distributional assumptions and is available in closed form.
However, it tends to underestimate τ . It often leads to zero estimates
for τ (in particular for small numbers of trials), and thus results in a
common effect meta-analysis with potentially too optimistic confidence
intervals for µ.
• REML: the restricted (or residual) maximum likelihood estimate has
been proposed as an improvement over the standard maximum likeli-
hood (ML) estimate (Viechtbauer, 2005). The REML estimate requires
iterative computations. It has the advantage of being less downward
biased compared to the DL and ML estimates.
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• MP: the Mandel-Paule (Paule and Mandel, 1982) estimate provides
an approximation to the REML estimate (Rukhin et al., 2000; DerSi-
monian and Kacker, 2007), like the DL estimate it does not require
distributional assumptions, and it has been recommended for use in
meta-analysis (Veroniki et al., 2015).
• BM : the Bayes-modal estimate (Chung et al., 2013) is an example of
a hybrid approach. In the first step, it derives a non-zero Bayesian
estimate for τ using a gamma prior with shape parameter α > 1, and
then proceeds in a classical way to infer µ in step (2). Effectively, this
is a penalized likelihood approach.
For step (2) we will use two methods to derive confidence intervals for µ for
each of the four τ estimates.
• The simple normal approximation (4), which ignores the uncertainty
for τˆ . The 1 − α confidence interval is constructed as µˆ ± z1−α/2 σµ
where zγ is the γ-quantile of the standard normal distribution and σµ
the standard error of µˆ given by σµ =
√
1
w+
.
• The method by Hartung and Knapp (Hartung and Knapp, 2001a,b;
Knapp and Hartung, 2003). Their method assumes an estimate µˆ has
been obtained (e.g. based on the DL estimate for τ , which also implies
weights wj in (5)). Based on these quantities, the variance estimate for
µˆ is obtained as qσ2µ with
q =
1
k − 1
∑
j
wj(yj − µˆ)2. (7)
The variance estimator qσ2µ can be interpreted as a weighted extension
of the usual empirical variance of the study-specific estimator. How-
ever, there are additional results which make qσ2u attractive (Hartung
and Knapp, 2001a,b; Knapp and Hartung, 2003): qσ2µ is an unbiased
estimate of Var(µˆ), and w+(k−1)qσ2µ follows a χ2k−1 distribution. This,
in turn, leads to the construction of an 1− α confidence interval for µ
as µˆ±tk−1;1−α/2 √q σµ. Here we use the modified version replacing q by
q⋆ with q⋆ := max{1, q} (Ro¨ver et al., 2015). Furthermore, this interval
provides coverage for µ close to the nominal level (Sidik and Jonkman,
2003), at least when the number of studies is sufficiently large.
In the Bayesian approach, uncertainty about τ is automatically accounted
for when estimating µ. However, the choice of prior matters, in particular if
the number of studies is small. This case has been discussed in Turner et al.
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(2015), Section 2 of Dias et al. (2012), and Section 6.2 of Dias et al. (2014).
While we suggest to use informative priors for τ if solid information about
between-trial heterogeneity is available, in what follows we will only consider
the case where prior information is weak. For this case, we recommend to use
priors that put most of their probability mass to values that represent small
to large between-trial heterogeneity and leave the remaining probability (e.g.
5%) to values that reflect very large heterogeneity. These weakly-informative
priors can be represented by half-normal, half-Cauchy, or half-t distributions
(Spiegelhalter et al., 2004; Gelman, 2006; Polson and Scott, 2012).
What constitues small to large heterogeneity depends on the parameter
scale. The situation we consider here is the two-group (test vs. control) bino-
mial case with parameters πTj and πCj for study j. The numbers of patients
in the test and control group are denoted by nTj and nCj, respectively, while
the numbers of events are denoted by rTj and rCj . Here the log-odds-ratio
θj is used for comparison. The corresponding approximate NNHM assumes
exchangeable log-odds-ratios across trials
θj = log
(
πTj(1− πCj)
πCj(1− πTj)
)
∼ N(µ, τ 2) (8)
and approximately normal log-odds-ratio estimates Yj with standard errors
sj
Yj = log
(
rTj(nCj − rCj)
rCj(nTj − rTj)
)
, s2j = 1/rTj+1/(nTj−rTj)+1/rCj+1/(nCj−rCj).
(9)
We will use half-normal priors HN(ϕ) that cover the range of typical
τ values representing small to very large heterogeneity: 0.125 (small), 0.25
(moderate), 0.5 (substantial), 1 (large), and 2 (very large); see Spiegelhalter
et al. (2004). A half-normal distribution HN(ϕ) with scale ϕ results from
taking absolute values of observations sampled from a normal distribution
with expectation 0 and variance ϕ2. To illustrate between-trial heterogeneity
for these τ values, Table 1 shows 95%-intervals for across-trial odds-ratios
(conditional on µ = 0). In Table 2 the three “weakly-informative” priors
are shown which we will use in the following sections. These are two half-
normal priors with scale 0.5 and 1, and a uniform (0,4) prior. The latter,
which puts 50% prior probability on very large between-trial heterogeneity
(in most cases a rather unrealistic assumption) will be used to assess prior
sensitivity.
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Table 1: Between-trial heterogeneity for log-odds-ratios: τ values represent-
ing small to very large heterogeneity, with 95%-intervals for across-trial odds-
ratios (exp(θj)).
heterogeneity 95% interval
small: τ = 0.125 0.783− 1.28
moderate: τ = 0.25 0.613− 1.63
substantial: τ = 0.5 0.325− 2.66
large: τ = 1 0.141− 7.10
very large: τ = 2 0.020− 50.4
Table 2: Between-trial heterogeneity for log-odds-ratios: three priors covering
small to large heterogeneity.
prior distribution median 95% interval
half-Normal(scale=0.5) 0.337 (0.016, 1.12)
half-Normal(scale=1.0) 0.674 (0.031, 2.24)
Uniform(0,4) 2.0 (0.1, 3.9)
4 Simulation study
In order to compare the performance of the different approaches to construct
credibility or confidence intervals for the treatment effect µ introduced in
Section 3, we conducted an extensive simulation study. The simulation sce-
narios are similar to those considered in Chung et al. (2013) and Brockwell
and Gordon (2001), but extend to smaller numbers of studies included in
the meta-analyses and to more pronounced between-trial heterogeneity to
reflect the particular circumstances frequently encountered in small popula-
tions and rare diseases. We generated data according to the model described
in Section 3, where we varied the number of studies involved (k ∈ {3, 5, 10}),
the true heterogeneity present (τ 2 ∈ {0, 0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1.0, 2.0}),
and where the individual studies’ associated standard errors are generated
based on draws from a χ2-distribution as described in Brockwell and Gordon
(2001). We then investigated the estimation accuracy for heterogeneity τ
and effect µ by logging the resulting estimates (marginal posterior median
in case of the Bayesian methods) and the coverage of true values for confi-
dence and credibility intervals. The simulations were carried out with 10,000
replications per scenario.
Since some readers might be more familiar with the I2 measure to capture
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the extend of heterogeneity than τ 2, we report here median values of the
simulated I2 depending on τ 2 for illustrative purposes. For instance, τ 2 =
0.02, 0.10, 0.5, 2 resulted in median I2 of 0.11, 0.37, 0.75, and 0.92.
Figure 2 shows the bias of several estimators of τ , given various numbers
of studies k included in the meta-analyses and a range of true values of τ .
The extent of bias strongly depends on the number of studies k for all estima-
tors considered with small bias for large k and substantial bias in situations
typically encountered in small populations research. Here the direction and
size of bias largely depends on the value of the τ itself and the estimator.
For small τ the bias can naturally be only positive. For medium to large
between-trial heterogeneity the likelihood estimators and the DL estimator
tend to underestimate τ whereas the Bayesian methods tend to overestimate
the between-trial heterogeneity. For very large τ the picture changes again
with some of the Bayesian methods leading to estimates which are in ex-
pectation well below the true value depending on the choice of prior. For
large and very large τ the likelihood based estimators and the DL display
substantial negative bias.
For those estimators that are not strictly positive by construction (i.e.
DL, REML and MP), Figure 3 shows the proportion of estimates of the
between-study heterogeneity τ equal to zero depending on the number k of
studies included in the meta-analyses. In particular for small k the proportion
of estimates being equal to 0 is substantial for small to moderate τ . This
effect diminishes with increasing k. As for the bias, the differences between
the three estimators are rather small.
Given the differences between the seven estimators of τ one might expect
that this would result in differences in estimating µ. Interestingly, we did
not observe any marked differences in the root mean squared error for the
corresponding estimators of the treatment effect µ with all differences being
below 9% and discrepancies vanishing with increasing τ and larger k (data
not shown).
Figure 4 shows the coverage of several credibility and confidence intervals
for the treatment effect µ depending on the between-trial heterogeneity τ 2
and the number of included studies k. When considering the bias in esti-
mating τ above, no estimator outperformed the others over the range of the
considered scenarios. Comparing the various approaches with regard to the
coverage probabilities of the credibility and confidence intervals for µ, how-
ever, the picture becomes much clearer. The frequentist methods based on
normal approximation achieve coverage probabilites at or above the nominal
level only for relatively small τ (i.e. τ ≤ 0.1), for which the Bayesian meth-
ods as well as the Knapp-Hartung method are conservative. For most other
values of τ the Bayes and Knapp-Hartung methods outperform the normal
10
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Figure 2: Bias in estimating the between-study heterogeneity τ for various
estimators and for several numbers k of studies included in the meta-analyses.
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Figure 3: Proportion of estimates of the between-study heterogeneity τ equal
to zero for those estimators that are not strictly positive by construction
depending on the number k of studies included in the meta-analyses.
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approximation approaches in that they provide higher coverage probabili-
ties. However, also for Bayesian and Knapp-Hartung methods the actual
coverage can deviate from the nominal confidence level substantially. With
appropriate choice of the prior distribution the coverage probabilities of the
Bayesian credibility intervals are often closer the the nominal level than the
Knapp-Hartung method. The differences between the various methods are
not only due to differences in estimating τ , but also reflect differences in the
construction of the intervals. By construction the Bayesian credibility inter-
vals are guaranteed to produce coverage probabilities of the nominal level
when averaged over the prior distribution. Here we consider coverage prob-
abilities at fixed τ and therefore expect the coverage probabilities to vary
with τ . The frequentist methods considered achieve the coverage probability
asymptotically, but their characteristics for finite samples are not obvious.
This can be seen in Figure 4 where the coverage probabilities are closer to
the nominal level for larger k.
Figure 5 shows the simulated mean lengths of several credibility and con-
fidence intervals for the treatment effect µ depending on the between-trial
heterogeneity τ 2 and the number of included studies k. By construction
the confidence intervals based on normal approximation are shorter than the
Knapp-Hartung intervals. The Bayesian intervals tend to be shorter than
the Knapp-Hartung intervals, also in situations with similar or even larger
coverage probability.
In conclusion, the method based on normal quantiles cannot be recom-
mended for use with small numbers of studies, since the observed coverage
was often well below the nominal level. The Knapp-Hartung approach leads
to coverage at or above the nominal level, but in cases with very few studies
results in extremely long confidence intervals. Bayesian credibility intervals
with appropriate choice of prior performed well and can be recommended
for application in rare diseases. However, with very small number of studies
included the results are sensitive to the prior specification.
5 The motivating case study revisited
In this section we are returning to the case study by Crins et al. (2014) in-
troduced in Section 2. Crins et al. investigated immunosuppressive therapies
in paediatric liver transplantation with regard to acute and steroid-resistant
rejections. In the first part of this section we will apply the methods in-
troduced in Section 3 to these data and discuss the results. In the second
part we will investigate the long-run behaviour of the different meta-analysis
procedures based on scenarios motivated by the liver transplant example sim-
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Figure 4: Coverage probability for credibility / confidence intervals for the
overall treatment effect µ depending on the between-study heterogeneity τ
and several numbers k of studies included in the meta-analyses using various
estimators.
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Figure 5: Mean lengths of the credibility / confidence intervals for the over-
all treatment effect µ depending on the between-study heterogeneity τ and
several numbers k of studies included in the meta-analyses using various
estimators.
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ulating binomial data rather than normal test statistics and their standard
errors.
Figure 6 shows the results of applying the various methods introduced
in Section 3 to the paediatric liver transplant data presented in Section 2.
In the figure the treatment effect estimates are shown on the log odds ratio
scale with 95% CI for the individual studies as well as for the meta-analyses.
The estimates τˆ of the between-trial heterogeneity are also included in the
figure. For the Bayes methods the posterior medians are given. Whereas in
the case of acute rejections the results are fairly similar across the various
methods with statistically significant combined treatment effects as reported
in Crins et al. (2014), there are some marked differences between the methods
in the case of steroid-resistant rejections. On the whole the methods based on
normal approximation lead to the shortest confidence intervals which are in-
dicating statistically significant effects with the exception of the BM method.
The Knapp-Hartung approach leads to intervals including 0 independent of
the heterogeneity estimation method and are among the longest intervals
obtained. With only three studies included in the SRR meta-analyses, the
differences between the Knapp-Hartung and the normal approaches are more
pronounced than in the AR example. In this example the Bayes methods
provide a middle ground with credibility intervals which are on the whole
shorter than those obtained by the Knapp-Hartung method and upper cred-
ibility limits close to 0 with the only exception being the estimate based on
the conservative uniform prior. However, due to the very small number of
studies the Bayes estimators are more sensitive to the specification of prior
than in the AR example with six trials.
In the AR example the estimates of the between-trial heterogeneity τ
center around 0.5 and vary from 0.37 with the MP estimator to 0.62 for the
BM estimator and the Bayes estimator with uniform prior on the interval
from 0 to 4. In the SRR data the observed heterogeneity is somewhat higher
in comparison with estimates ranging from 0.33 for the MP estimator to 1.11
for the Bayes estimator with uniform prior. All these estimates come with
a considerable degree of uncertainty reflected in the length of the confidence
/ credibility intervals. For the acute rejections the 95% credibility intervals
of τ are 0 to 1.848 with uniform prior, to 1.260 with half-normal prior with
scale 1, and to 0.862 for half-normal prior with scale 0.5 whereas the 95%
confidence interval using the Q-profile method extends from 0 to 1.726. For
the steroid-resistant rejections the 95% credibility intervals range from 0 to
3.368, 1.652, and 0.941 for the uniform and the two half-normal priors with
scales 1 and 0.5, respectively. The 95% Q-profile interval even extends from
0 to 5.365. As can be seen from this example, the credibility intervals depend
very much on the choice of prior, in particular with very small numbers of
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Figure 6: Paediatric transplant example: Treatment effect estimates on the
log odds ratio scale with 95% confidence intervals for the individual studies
and meta-analyses as well as estimates τˆ of the between-trial heterogeneity.
For the Bayes methods the posterior medians are given.
studies. The frequentist Q-profile method gives confidence intervals as wide
or wider than the credibility intervals based on the conservative uniform
prior.
We exemplarily investigated the long-run behaviour of the different meta-
analysis procedures based on scenarios motivated by the liver transplant
example. For this purpose we simulated data similar to the meta-analyses
of acute rejections and steroid-resistant rejections. The former included six
studies, the latter included only three. In each simulation iteration, first
true group-specific odds were generated as normally distributed on the log-
odds scale; for AR with means µcontrol = 0.0 and µtreatment = −1.5 and
for SR with µcontrol = −2.0 and µtreatment = −3.0. Variances were equal
to 1, and the log-odds were positively correlated with correlation coefficient
0.875 and 0.719 for AR and SRR, respectively. The resulting between-trial
heterogeneity in terms of log-odds ratios is τ = 0.5 for ARR and τ = 0.75 for
SRR, which are substantial and substantial to large levels of hetereogeneity
according to Table 1. Resulting log-odds were then used to generate study
results (contingency tables) based on a binomial distribution and patient
numbers as given in the examples. The corresponding effect size estimates
and standard errors were computed using the escalc() function from the
metafor package (Viechtbauer, 2010), which were then analyzed using the
different methods. The results of these simulations are summarized in Table 3
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where the coverage probabilities and mean lengths of the 95% confidence
intervals for the treatment effect µ are given. As with the simulation study
presented in Section 4, 10,000 trials were simulated for each scenario.
Looking at Table 3 it is apparent that the confidence intervals based on
the normal quantiles have coverages below the nominal level of 0.95 with the
exception of the interval using the BM estimator of the between-trial het-
erogeneity τ , which is slightly conservative in both scenarios. The Knapp-
Hartung confidence intervals are in comparison much longer and fairly con-
servative. In the SRR scenario this is more extreme due to the very small
number of trials. Although the true between-trial heterogeneity is substan-
tial (τ = 0.5) in the AR scenario and substantial to large (τ = 0.75) in the
SRR scenario the proportion of estimating 0 for τ is relatively large, explain-
ing partly the disappointing performance of some frequentist procedures. In
the ARR scenario the proportions are 0.333, 0.255, and 0.292 with the DL,
REML and MP estimator, respectively. In the SRR setting the proportions
are 0.523, 0.447, and 0.487. The interval with the coverage probabilities clos-
est to the nominal level of 0.95 out of all interval estimators investigated is
the Bayes credibility interal with half normal prior and scale 0.5. The more
conservative choices of prior distributions of τ , i.e. uniform on the interval
from 0 to 4 and half-normal with scale 1, lead to longer and more conserva-
tive credibility intervals. Again the dependence of the coverage probabilities
on the the prior selected is more pronounced in the SRR scenario with fewer
studies than in the AR scenario.
The results of this small simulation generating data from binomial dis-
tributions tie in nicely with the extensive simulation study presented in Sec-
tion 4 where effect estimates and their standard errors were sampled directly.
In comparing back, one should note that the magnitude of the heterogeneity
τ may not be directly comparable to the values used in the simulations in
Section 4. In the simulations, the studies’ standard errors σi were drawn from
a distribution ranging from 0.095 to 0.775 (with median 0.35), while in the
paediatric transplantation example, the standard errors ranged from 0.056
to 1.529 for AR and from 0.676 to 1.142 for SRR, so that the same absolute
heterogeneity τ corresponds to a smaller relative amount of heterogeneity
(e.g. I2) in the transplantation example than in the previous simulations.
6 Discussion
In rare diseases and small populations data and biomaterial of an individual
patient are even more precious due to their rarity. In these circumstances the
synthesis of the evidence available is an important step in the development
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Table 3: Comparison of different methods using simulations of binary data
imitating the example settings. Coverage probabilities (mean lengths) of 95%
confidence intervals for the treatment effect µ are given.
AR SRR
DL-norm 93.1 (1.28) 91.7 (2.51)
REML-norm 92.8 (1.27) 91.7 (2.50)
EB-norm 93.2 (1.29) 91.7 (2.51)
BM-norm 96.7 (1.46) 97.9 (3.24)
DL-KnHa 98.0 (1.71) 99.9 (5.58)
REML-KnHa 98.1 (1.71) 100.0 (5.58)
EB-KnHa 98.0 (1.70) 99.9 (5.52)
BM-KnHa 99.4 (1.92) 100.0 (7.12)
Uniform(0,4) 99.0 (1.91) 100.0 (4.84)
half-Normal(1.0) 97.8 (1.55) 98.0 (3.00)
half-Normal(0.5) 95.5 (1.30) 94.2 (2.38)
of new treatments. Meta-analyses in rare diseases and small populations
face particular problems which can be characterized by a small number of
studies included in the meta-analysis, relatively small study sizes, and het-
erogeneity between study results which might be due to a variety of study
designs employed. In this paper we reviewed a number of frequentist and
Bayesian procedures and investigated their suitability for meta-analyses in
rare diseases and small populations.
In summary, we found that frequentist estimators of the between-trial
heterogeneity often fail to pick up the variation present in the data, in par-
ticular when the number of trials is very small (e.g. k = 3), resulting in a
relatively high proportion of estimates being 0. The observed downwards bias
is in agreement with previous findings (see e.g. Chung et al. (2013); Bo¨hning
et al. (2002)). Furthermore, the commonly applied approach of constructing
confidence intervals using normal quantiles fails to reflect the uncertainty
in the estimation of the between-trial heterogeneity. This has been rec-
ognized before and methods based on t-distributions have been proposed
to tackle the problem (Follmann and Proschan, 1999; Hartung and Knapp,
2001a,b; Knapp and Hartung, 2003; Higgins et al., 2009). Here we included
the method by Knapp-Hartung in our investigations. Their approach yields
more favourable results in terms of coverage probabilities of the confidence in-
tervals than the standard approach based on normal quantiles (Hartung and
Knapp, 2001a,b). As we have seen in the simulations presented here, the
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Knapp-Hartung approach controls the coverage probability even in settings
with very few small studies, which was also demonstrated in a very recent
commentary for the case of only two studies (k = 2) (Gonnermann et al.,
2015). As we have seen here, however, these intervals are often very long
and fairly conservative, which again is in agreement with previous findings
(Gonnermann et al., 2015; Harbord and Higgins, 2008).
The Bayesian credibility intervals based on uniform and half-normal pri-
ors also exhibited coverage probabilities in excess of the nominal level for a
range of scenarios considered. However, they tended to be shorter than those
obtained by the Knapp-Hartung method while producing coverage probabil-
ities either similar to the Knapp-Hartung method or closer to the nominal
level. With very few studies the performance of the Bayesian credibility inter-
vals is of course sensitive to the specification of the prior for the between-trial
heterogeneity (Lambert et al., 2005). On the whole the proposed half-normal
priors with scales 0.5 or 1 performed well across the scenarios considered,
which we believe reflect typical situations encountered in rare diseases as
evidenced by our example in immunosuppression after liver transplantation
in children. Therefore, we would recommend this choice of prior for appli-
cations in rare diseases and small populations. Furthermore, these priors
are also supported by empirical evidence reported in Turner et al. (2015).
With larger numbers of studies of course the prior specification becomes less
important.
Frequentist and Bayesian appproaches to interval estimation in meta-
analyses have been compared elsewhere (Chung et al., 2013). However, our
comparisons were not only different by focussing on scenarios typical for rare
diseases and small populations, but also in the range of scenarios consid-
ered and number of simulation replications performed. We were able to run
this relatively extensive simulation study including computationally intensive
fully Bayesian approaches because of an advance in their implementation re-
sulting in the R package bayesmeta moving away, as very recently suggested
in Turner et al. (2015), from standard Markov chain Monte Carlo techniques.
Our investigations were limited to a small number of estimators of the
between-trial heterogeneity τ . These included standard estimators commonly
applied in meta-analyses such as the DerSimonian-Laird estimator, but also
the recently proposed Bayes-Modal estimator by (Chung et al., 2013). How-
ever, a number of alternative estimators of τ have been proposed which have
been compared elsewhere (Veroniki et al., 2015). Furthermore, we focused
here on meta-analyses including a small number of studies (k ≤ 10) which
was motivated by rare diseases and small populations. However, this is
also otherwise not uncommon as a review by Turner et al. of the Cochrane
Database shows (Turner et al., 2012). We also restricted simulations to nor-
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mally distributed outcomes, without considering the effects of transforming
other types of outcomes to a continuous scale. Such effects become espe-
cially relevant when approximate normality breaks down, as for example
when dealing with data on rare events (Bradburn et al., 2007).
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